Drug intelligence / Profile preview

lisinopril + hydrochlorothiazide

Development stage
Approved
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Lisinopril + hydrochlorothiazide is a fixed-dose combination medication used to treat high blood pressure (hypertension). It combines two active ingredients: * Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, which works by blocking the formation of angiotensin II, a substance that causes blood vessels to constrict. This leads to relaxation of blood vessels and lower blood pressure. * Hydrochlorothiazide, a thiazide diuretic ("water pill"), which helps the kidneys remove excess water and sodium from the body through urine, further lowering blood pressure. This combination is indicated for patients whose blood pressure is not adequately controlled with monotherapy. Lowering high blood pressure reduces the risk of stroke, heart attack, kidney failure, and other complications[1][2][4][8].

Brand names
ZestoreticPrinzide
Other names
lisinopril/hydrochlorothiazidehydrochlorothiazide and lisinoprillisinopril/hctz
02

Targets

ACE (Angiotensin Converting Enzyme)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on lisinopril + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lisinopril + hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call